Samuel Kirimunda

497 total citations
12 papers, 163 citations indexed

About

Samuel Kirimunda is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Samuel Kirimunda has authored 12 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 7 papers in Epidemiology and 3 papers in Surgery. Recurrent topics in Samuel Kirimunda's work include Tuberculosis Research and Epidemiology (6 papers), vaccines and immunoinformatics approaches (2 papers) and HIV Research and Treatment (2 papers). Samuel Kirimunda is often cited by papers focused on Tuberculosis Research and Epidemiology (6 papers), vaccines and immunoinformatics approaches (2 papers) and HIV Research and Treatment (2 papers). Samuel Kirimunda collaborates with scholars based in Uganda, United States and Sweden. Samuel Kirimunda's co-authors include Moses Joloba, Deus Lukoye, Francis Adatu, Fred Nuwaha, Frank Cobelens, Harriet Mayanja‐Kizza, Gunilla Källenius, Noah Kiwanuka, Lois Bayigga and Agnes Kiragga and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and BMC Infectious Diseases.

In The Last Decade

Samuel Kirimunda

12 papers receiving 160 citations

Peers

Countries citing papers authored by Samuel Kirimunda

Since Specialization

Citations

This map shows the geographic impact of Samuel Kirimunda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Kirimunda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Kirimunda more than expected).

Fields of papers citing papers by Samuel Kirimunda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Kirimunda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Kirimunda. The network helps show where Samuel Kirimunda may publish in the future.

Co-authorship network of co-authors of Samuel Kirimunda

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Kirimunda. A scholar is included among the top collaborators of Samuel Kirimunda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Kirimunda. Samuel Kirimunda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease 2018 ·BMC Infectious Diseases ·(unknown), (unknown), Samuel Kirimunda, Robert Downing, (unknown), Edward Mbidde, Jacqueline Weyer, Janusz T. Pawęska, Moses Joloba, Misaki Wayengera	7
2	Performance of the QuantiFERON^®-TB Gold In-Tube assay in tuberculin skin test converters: a prospective cohort study 2018 ·The International Journal of Tuberculosis and Lung Disease ·María Eugenia Castellanos, Samuel Kirimunda, Leonardo Martínez, (unknown), (unknown), (unknown), Andreas Handel, Sarah Zalwango, Noah Kiwanuka, Christopher C. Whalen	11
3	Cervical cancer risk perceptions, sexual risk behaviors and sexually transmitted infections among Bivalent Human Papillomavirus vaccinated and non-vaccinated young women in Uganda - 5 year follow up study 2017 ·BMC Women s Health ·Edward Kumakech, Sören Andersson, Henry Wabinga, (unknown), Samuel Kirimunda, Vanja Berggren	5
4	Sero-diagnosis of Active Mycobacterium tuberculosis Disease among HIV Coinfected Persons using Thymidylate Kinase based Antigen and Antibody Capture Enzyme Immuno-Assays 2017 ·PubMed ·Misaki Wayengera, (unknown), (unknown), (unknown), David Patrick Kateete, Eddie M. Wampande, Samuel Kirimunda, Lois Bayigga, (unknown), (unknown), Benon Asiimwe, Moses Joloba	4
5	Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda 2017 ·Malaria Journal ·Marlena Maziarz, (unknown), Isaac Otim, Paul Kagwa, (unknown), Ismail D. Legason, Martin D. Ogwang, Samuel Kirimunda, Benjamin Emmanuel, Steven J. Reynolds, Patrick Kerchan, Moses Joloba, Andrew W. Bergen, Kishor Bhatia, Ambrose Talisuna, Robert J. Biggar, James J. Goedert, Ruth M. Pfeiffer, Sam M. Mbulaiteye	17
6	Immuno-diagnosis of Mycobacterium tuberculosis in sputum, and reduction of timelines for its positive cultures to within 3 h by pathogen-specific thymidylate kinase expression assays 2017 ·BMC Research Notes ·Misaki Wayengera, (unknown), (unknown), (unknown), David Patrick Kateete, Eddie M. Wampande, Samuel Kirimunda, Edgar Kigozi, Fred Ashaba Katabazi, (unknown), Samuel Kyobe, (unknown), Benon Asiimwe, Moses Joloba	6
7	Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda 2016 ·PLoS ONE ·Edward Kumakech, Vanja Berggren, Henry Wabinga, Gabriella Lillsunde‐Larsson, Gisela Helenius, (unknown), Mats G. Karlsson, Samuel Kirimunda, (unknown), Sören Andersson	8
8	Association between human leukocyte antigen class II and pulmonary tuberculosis due to mycobacterium tuberculosis in Uganda 2015 ·BMC Infectious Diseases ·(unknown), (unknown), Samuel Kirimunda, Gunilla Källenius, Moses Joloba	19
9	CD4 T-cell activation and reduced regulatory T-cell populations are associated with early development of cataracts among HIV-infected adults in Uganda 2014 ·Immunology Letters ·Damalie Nakanjako, (unknown), Isaac Ssewanyana, Rose Nabatanzi, Lois Bayigga, Samuel Kirimunda, Moses Joloba, Yukari C. Manabe, Andrew Kambugu, Robert Colebunders, Harriet Mayanja‐Kizza	9
10	High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort 2014 ·BMC Immunology ·Lois Bayigga, Rose Nabatanzi, Prossy Naluyima, Harriet Mayanja‐Kizza, Moses R. Kamya, Andrew Kambugu, Joseph Olobo, Agnes Kiragga, Samuel Kirimunda, Moses Joloba, Damalie Nakanjako	17
11	Distinct T-Cell Responses When BCG Vaccination Is Delayed From Birth to 6 Weeks of Age in Ugandan Infants 2013 ·The Journal of Infectious Diseases ·(unknown), Benjamin M. Kagina, Anne Wajja, (unknown), (unknown), Samuel Kirimunda, E. Jane Hughes, Noah Kiwanuka, Moses Joloba, (unknown), Thomas J. Scriba, Harriet Mayanja‐Kizza, Cheryl L. Day, Willem A. Hanekom	24
12	Rates of Anti-Tuberculosis Drug Resistance in Kampala-Uganda Are Low and Not Associated with HIV Infection 2011 ·PLoS ONE ·Deus Lukoye, Frank Cobelens, (unknown), Samuel Kirimunda, Francis Adatu, (unknown), Fred Nuwaha, Moses Joloba	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact